Sugi Predict

Sugi Predict / Compounds / SCHEMBL2469031

SCHEMBL2469031

SCHEMBL2469031

Nc1ccc2[nH]nc(-c3ccc(F)cc3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 2/20 0.55
▸ HTR2A P28223 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ HTR2B P41595 1/20 0.50
▸ MAP2K4 P45985 5/20 0.49
▸ MAP2K7 O14733 1/20 0.48
▸ FGFR1 P11362 1/20 0.48
▸ FGFR2 P21802 1/20 0.48
▸ AURKA O14965 1/20 0.47
▸ NTRK1 P04629 2/20 0.47
▸ CSNK1D P48730 2/20 0.47
▸ MAPK1 P28482 4/20 0.47
▸ MAPK6 Q16659 3/20 0.47
▸ MAPKAPK2 P49137 2/20 0.47
▸ MAPKAPK3 Q16644 2/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.46
▸ MAPKAPK5 Q8IW41 1/20 0.46
▸ MAPK13 O15264 1/20 0.46
▸ MAPK12 P53778 1/20 0.46
▸ MAPK11 Q15759 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27750634 0.98 AXL (0.54) AXLHTR2AHTR2CHTR2BMAP2K4
SCHEMBL1663211 0.90 AXL (0.60) AXLHTR2AHTR2CHTR2BMAP2K4
SCHEMBL4226130 0.87 MAP2K4 (0.61) AXLMAP2K4MAP2K7FGFR1FGFR2
SCHEMBL5372660 0.84 FGFR1 (0.44) AXLMAP2K4MAP2K7FGFR1FGFR2
SCHEMBL5372663 0.84 FGFR1 (0.44) AXLMAP2K4MAP2K7FGFR1FGFR2
SCHEMBL12193576 0.84 TRPA1 (0.54) AXLHTR2AHTR2CHTR2BMAP2K4
SCHEMBL4006856 0.83 AXL (0.55) AXLHTR2AHTR2CHTR2BMAP2K4
SCHEMBL5387121 0.83 MAPK13 (0.49) AXLMAP2K4MAP2K7FGFR1FGFR2
SCHEMBL12193658 0.83 MKNK1 (0.61) AXLHTR2AHTR2CHTR2BFGFR1
SCHEMBL4008208 0.83 DCLK1 (0.65) AXLHTR2AHTR2CHTR2BMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 — — US claimed
EP-1633740-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-11-19 — — EP claimed
JP-2007516173-A — — 2007-06-21 — — JP claimed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 — — US claimed
EP-1633740-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2006-03-15 — — EP claimed
WO-2004112719-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 — — WO claimed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 — — US disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 — — US disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 — — US disclosed
EP-2155722-B1 POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME (US) 2013-08-14 — — EP disclosed
EP-2155722-B1 POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME (US) 2013-08-14 — — EP disclosed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 — — EP disclosed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 — — EP disclosed
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-07-01 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed
US-20040077877-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. 2004-04-22 — — US disclosed
EP-1313711-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2003-05-28 — — EP disclosed
WO-2002010137-A9 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARM INC (US) 2003-02-06 — — WO disclosed
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC 2002-08-01 — — US disclosed
WO-2002010137-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 AXL 462/4885HTR2A 3852/4885HTR2C 2859/4885
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK MAPK1, MAP3K1, MAPKAPK2 AXL 4600/4885HTR2A 3102/4885HTR2C 3196/4885
US-20040077877-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 AXL 2473/4885HTR2A 2954/4885HTR2C 2138/4885
US-20070099944-A1 Chemical compounds ROCK1, ROCK2, CIT AXL 1103/4885HTR2A 2932/4885HTR2C 2523/4885
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 AXL 2473/4885HTR2A 2954/4885HTR2C 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.